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The immunodominant epitope α-D-Galp-(1→3)-β-D-Galp-(1→4)-D-GlcNAc, 
expressed in the mucins of the infective trypomastigote stage of Trypanosoma cruzi has 
been proposed for multiple clinical applications, from serodiagnosis of protozoan caused 
diseases to xenotransplantation or cancer vaccinology. It was previously shown that the 
analogue trisaccharide, with glucose in the reducing e d instead of GlcNAc, was as 
efficient as the natural trisaccharide for recognition of chagasic antibodies. Here we 
describe the synthesis of α-D-Galp-(1→3)-β-D-Galp-(1→4)-D-Glcp functionalized as the 
6-aminohexyl glycoside and its conjugation to BSA using the squarate method. The 
conjugate of 6-aminohexyl α-D-Galp-(1→3)-β-D-Galp was also prepared. Both 
neoglycoconjugates were recognized by serum samples of Trypanosoma cruzi-infected 





















American trypanosomiasis, or Chagas disease, is a life-threatening infection caused 
by the protozoan parasite Trypanosoma cruzi, for which no vaccines or appropriate 
treatments are available. Current estimations indicate that ~6 million people are already 
infected and that ~100 million individuals are at risk of infection [1]. In endemic areas of 
Latin America, the parasite is primarily transmitted to humans through the bite of infected, 
blood-sucking triatomine bugs. Individuals may also be infected through blood transfusion, 
organ transplantation, congenital contamination or by the ingestion of tainted food and 
fluids [1]. 
The diagnosis of Chagas disease is challenging becaus  it is often asymptomatic in its 
acute phase and evolves into a chronic stage in which it may present diverse clinical forms 
[1]. In addition, and due to the very low or null parasitemia during the chronic phase, the 
detection of parasites in blood samples by direct examination and/or by parasite-
amplification methods such as hemoculture or xenodiagnoses is difficult and time-
consuming. Several molecular methods, although highly specific, present suboptimal 
sensitivity and require technological expertise and expensive laboratory equipment 
(reviewed in [2]). Therefore, detection of anti-T. cruzi antibodies remains the most effective 
method for demonstrating direct exposure to the parasite. At present, the most widely used 
serologic methods are indirect hemagglutination assay (IHA), indirect immuno-
fluorescence assay (IIF), and enzyme-linked immunosorbent assay (ELISA). Synthetic 
peptides spanning linear B-cell epitopes identified n parasite antigens may be used to 
increase serodiagnostic assay specificity [3][4][5]. 
The serodiagnostic potential of carbohydrate-rich molecules found on the surface of 
T. cruzi parasites has also been explored. In particular, the α-galactosyl-containing 
glycotopes that decorate the glycosylphosphatidylinositol (GPI)-anchored mucins 
(henceforth tGPI-mucins) of the bloodstream trypomastigote forms [6]. Since tGPI-mucins 
are expressed at staggering levels (i.e. ~106 molecules per parasite), and each may undergo 
multiple glycosylations, their attached α-galactosyl-containing glycotopes attached to them 
end up forming a quite dense and immunogenic ‘surface coat’ [7][8][9][10]. Structural data 













trisaccharide  α-D-Galp(1→3)-β-D-Galp(1→4)-D-GlcNAc (1) known as "α-Gal” [11]. In 
the remaining tGPI-mucins glycans, this core trisacch ride is branched with β-D-Galp 
residues, in as-yet undefined structures [12]. Once on the parasite surface, terminal β-D-
Galp units may be linked to sialic acid residues by means of the trans-sialidase reaction, 
thus leading to the formation of sialoglycomarkers c ucial for parasite protection and 
virulence [8][9][10][11][12][13][14][15].  
The α-Gal evolutionary distribution is unique, being abundantly expressed across the 
whole branch of mammals except for Old World monkeys, apes and humans [11]. Instead, 
these species produce large amounts of so-called anti α-Gal antibodies in response to cross-
reactive glycotopes present in commensal enterobacteri  [11]. Interestingly, the α-Gal 
glycotope is only weakly recognized by anti α-Gal antibodies from healthy individuals, 
whereas this structure and particularly the disacchride α-D-Galp-(1→3)-β-D-Galp (2), 
elicit a strong humoral response in patients infected with T. cruzi [12][16]. Therefore, 
purified tGPI-mucins and/or synthetic neoglycoconjugates bearing glycotopes 1 and/or 2 
were proven valuable tools for the improvement of serodiagnostic and therapy methods in 
Chagas disease [6][12][16] [17][18][19][20][21][22][ 3], and Leishmania and Plasmodium 
infections [11][24][25][26][27]. 
In addition to their diagnostic potential, antibodies to the αGal glycotope were proven 
to trigger the lysis of bloodstream trypomastigotes h nce raising the possibility that they are 
involved in controlling parasitemia during T. cruzi infection [9]. Indeed, vaccination of 
α1,3GalT knockout mice with α-Gal-containing neoglycoconjugates was shown to protect 
against lethal challenge with T. cruzi parasites, chiefly by inducing a strong, cytolytic anti 
α-Gal antibody-mediated humoral response [28]. Again, quite similar results were obtained 
with Leishmania and Plasmodium parasites in α1,3GalT knockout mouse models 
[29][30][31] indicating that the αGal glycotope constitutes an appealing candidate for the 
development of a prophylactic vaccine to block main protozoan infections. In broader 
terms, artificial modulation of the αGal glycotope content was explored as a general 
strategy to increase/decrease the immunogenicity of xenotransplants and viral and/or cancer 
vaccines [11][32][33]. 
In accordance to the numerous clinical applications f αGal, a multiplicity of 













The purpose of our current project is develop and execute an efficient synthesis of an 
α-Gal glycotope and conjugate it to polypeptide carriers, to obtain diagnosis tools for 
Chagas disease.  It was previously shown that the trisaccharide α-D-Galp(1→3)-β-D-
Galp(1→4)-β-D-Glcp (3), with glucose in the reducing end instead of GlcNA  was as 
effective for recognition of chagasic antibodies as the natural trisaccharide 1 [16]. Thus, β-
(1→4) glycosylation of D-GlcNAc derivatives being a difficult task [34], we decided to 
prepare trisaccharide 3 functionalized as the 6-aminohexyl glycoside 4 and conjugate it to 
BSA using the squaric acid chemistry [35], to afford 4-BSA (Figure 1). The “squarate 
method” was previously used for the preparation of many glycoconjugates, including 
experimental vaccines [36]. A BSA conjugate of 3 was previously obtained by a 
conjugation chemistry which used the sugar glycoside with a thiol reactive linker and 
maleimide activated BSA [16]. The squarate method has t e advantage of using a sugar 
derivative with a terminal amino group, which is more stable than the thiol group, and it 
does not require use of a derivatized peptide. 
 
Figure 1. Target trisaccharide and neoglycoconjugate 
 
 
2. Results and Discussion 
 
2.1 Synthesis of 6-aminohexyl α-D-Galp-(1→3)-β-D-Galp-(1→4)-β-D-Glcp (4) 
 
The synthesis of different derivatives of trisaccharide 3 has been previously 
accomplished. Wang et al. developed a downstream stepwise strategy [37]. Stocker and col. 
[38] and Almeida and col. [16] based their strategies on lactose glycosyl acceptors, lactose 













Galp-(1→4)-β-D-Glcp motif. This fact greatly simplifies the total synthesis. In our case, we 
also used lactose as starting material for the synthesis of 4. We planned that after a 
sequence of reactions leading to a selectively protect lactose, a glycosyl acceptor with the 
free OH-3' would be accessed, which could be then glycosylated with a α-D-Galp donor. 
Subsequently, a spacer carrying a reactive amino group would be introduced [39]. 
Therefore, the retrosynthetic analysis of target molecule 4 indicated that it could be 
obtained from precursors 6 [40] and 7 (Figure 2). 
 
 
Figure 2. Target trisaccharide 4 and synthetic precursors 6 and 7. 
 
By treatment of lactose with Ac2O/NaOAc, avoiding the use of pyridine or other 
solvents, per-O-acetylated lactose was obtained [41]. By glycosidation with thiocresol 
promoted by BF3.Et2O, followed by Zemplén deacetylation, we obtained 8 [42]
 (Scheme 1) 
with the anomeric S-tolyl function which could be later activated for further glycosylation 
with 6-aminohexanol. The differentiation of lactose OH-3' was performed by selective 
dibutyltinoxide-promoted alkylation with 4-methoxybenzyl chloride (PMBCl) [43] to yield 
compound 9 [44].  This strategy was also applied by Almeida et al. [16]. The pronounced 
downfield shift exhibited by C-3' (80.7 ppm) after 4-methoxybenzylation of 8, compared 
with lactose (72.6 ppm) [45], confirmed the site of substitution in compound 9. 
By O-benzoylation of 9, followed by oxidative O-demethoxybenzylation, glycosyl 
















Scheme 1. Synthesis of the lactosyl acceptor 7. Reagents and conditions: (a) Ac2O/NaOAc; 
(b) TolSH, BF3.OEt2, CH2Cl2; (c) NaOMe/MeOH, rt; (d) Bu2SnO, toluene, reflux; (e) 
NBu4I, PMBCl, toluene, reflux; (f) BzCl, pyridine, rt; (g) DDQ, CH2Cl2-H2O, rt. 
 
With derivative 7 in hand, the next step was to glycosylate it with donor 6  [40]. 
Thus, by treatment of a solution of these compounds with TMSOTf in Et2O at −55 ºC, the 
α-linked S-Tol trisaccharide 5 was obtained, as confirmed by the chemical shift of C-1’’ 
(94.6 ppm) and the J1’’,2’’  value (3.4 Hz) observed in the 
13C and 1H NMR spectra, 
respectively (Scheme 2). 
 
 
Scheme 2. Synthesis of 4. Reagents and conditions: (a) TMSOTf, Et2O, 4Å MS, −55 ºC; (b) 
6-Benzyloxycarbonylamino-1-hexanol, NIS, HOTf, CH2Cl2, 4 Å MS, rt; (c) NaOMe, 














The installation of the spacer was performed by activ tion of 5 with NIS/HOTf and 
reaction with 6-benzyloxycarbonylamino-1-hexanol, affording trisaccharide 11 in 74 % 
yield (Scheme 2). The 13C NMR spectrum of 11 showed in the anomeric region signals at δ
101.18 and 101.12 corresponding to C-1’ and C-1, respectively, confirming the β-O-
glycosidic character of the newly formed bond, and  signal at 94.7 ppm corresponding to 
C-1’’. 
Deprotection of 11 was done by consecutive O-deacylation with sodium methoxide 
and catalytic hydrogenolysis over 10% palladium on charcoal, in methanol containing 5% 
of formic acid. Free trisaccharide 4 was obtained in 93 % yield for two steps (Scheme 2). In 
the anomeric region of the 1H NMR spectrum doublets at δ 5.15 (J1’’,2’’ 3.9 Hz, H-1’’), 4.53 
(J1’,2’ 7.8 Hz, H-1’) and 4.49 (J1,2 8.0 Hz, H-1) were observed, and the 
13C NMR spectrum 
showed anomeric signals at 102.8 (C-1’), 101.9 (C-1) and 95.4 (C-1’’) ppm. The structure 
of 4 was further confirmed by the m/z observed in the HR ESI mass spectrum, 
corresponding to the calculated exact mass of the mol cule. 
 
2.2 Conjugation of 6-aminohexyl α-D-Galp-(1→3)-β-D-Galp-(1→4)-β-D-Glcp (4) to BSA 
 As part of our project, we planned the conjugation of several oligosaccharides both to 
BSA and to some peptides specifically chosen on the basis of their antigenic activity 
against α-Gal antibodies [46][47]. We intended to optimize a conjugation protocol for 
trisaccharide 4 to BSA, to establish an easy procedure to monitor the reaction and extend 
the conditions to the conjugation with other peptides. Several methods have been described 
for the conjugation of oligosaccharides to peptides and proteins [48][49][50][51]. However, 
many of them use oxidative or reducing conditions that can modify the structure of the 
oligosaccharide to be conjugated. On the other hand, monitoring the progress of the 
conjugation reaction is usually difficult. We decided to use here the "squarate method" [52] 















Scheme 3. Conjugation of trisaccharide 4 to BSA. Regents and conditions: (a) 3,4-
dimethoxy-3-cyclobutene-1,2-dione, KH2PO4-NaOH buffer (pH 7), rt; (b) BSA, borax -0.1 
M KH2PO4 buffer (pH 9), rt. 
 
Linker-equipped trisaccharide 4 was submitted to conjugation by the squarate method 
using conditions (hapten/peptide ratio, hapten and buffer concentrations, etc) optimized by 
Kovac and coworkers [53][54]. Dimethyl squarate was used as reagent, since it was 
described as the most convenient for conjugation [55]. Treatment of 4 with two equiv of 
dimethyl squarate at pH 7 afforded monomethyl monoamide squarate 4-sq (Scheme 3). 
Complete conversion was confirmed by TLC analysis (ee Experimental). Purification of 4-
sq from the buffer salts, the excess of dimethyl squarate and the monomethyl squarate 
formed as by product was performed by filtration through graphitized carbon SPE column. 
In the NMR spectra of 4-sq some of the signals were split, as it is usually observed for 
squarate derivatives due to the double bond nature of the vinilogous C-N linkage [35]. 
Thus, in the 1H NMR spectrum the signal corresponding to the OCH3 group was observed 
as two singlets integrating for three hydrogens at 4.38 and 4.36 ppm. The splitting was also 
observed in the signal for the CH2NH hydrogens of the linker, which as result of the 
substitution by the squarate were shifted downfield, from 3.00 ppm (triplet) in 4 to 3.48 and 
3.62 ppm (two triplets) in 4-sq. Diagnostic signals were also observed in the 13C NMR 
spectrum: split signals corresponding to the OCH3 group at 60.8 and 60.9 ppm and to the 













Subsequently, 4-sq was treated at pH 9 with BSA, in a 50:1 ratio, to afford the 
glycoconjugate. Also at this stage TLC was useful to monitor the reaction (see 
experimental). The conjugation mixture was subjected to dialysis which allowed the 
separation of the excess of 4-sq and the salts. Lyophilization then afforded the 
neoglycoconjugate 4-BSA, whose MALDI spectrum showed high glycosylation and 
absence of the unconjugated BSA (Figure 3). 
Figure 3. MALDI-TOF-MS spectra of free BSA and conjugates 2-BSA, 4-BSA and 12-
BSA. 
The synthesis and conjugation to BSA of the 6-aminohexyl glycosides of  α-D-Galp-
(1→3)-β-D-Galp (2) and  β-D-Galp (12) was performed in a similar way, affording 
glycoconjugates 2-BSA and 12-BSA (Figure 4, synthesis not shown). Aliquots of the 
conjugation mixtures were taken at different times, and analyzed by SDS-PAGE under 
denaturing conditions, followed by Coomasie Brilliant blue staining (Fig 5A). Results 
allowed to conclude that after 24 h the reaction was complete, since no unconjugated BSA 




















































Figure 5. SDS-PAGE (10 %) under denaturing conditions of the neoglycoconjugates. A) 
Samples containing ~1 µg of 12-BSA, 2-BSA or 4-BSA collected at either 24 or 48 h of the 
conjugation reaction. The gel was stained with Coomassie Brilliant blue. BSA was used as 
control. B) and C) Samples containing ~1 µg of 12-BSA, 2-BSA or 4-BSA collected at 48 
h of the conjugation reaction. The gel was stained with Schiff reagent (B), followed by 
Coomassie Brilliant blue (C). BSA and bovine submaxillary mucin (BSM) were used as 
negative and positive controls for Schiff reagent staining, respectively. Molecular markers 
(in kDa) are indicated. 
 
The neoglycoconjugates were characterized by MALDI-TOF-MS (Figure 3). The 
apparent molecular mass observed for these neoglycoconjugates (~80 kDa for 12-BSA, and 
~85 kDa for both 2-BSA and 4-BSA, Figure 5A) in the SDS-PAGE, strongly correlate with 
MALDI-TOF-MS data. The sugar load of the conjugates was estimated on the basis of the 
shift in the molecular mass of the BSA (Table 1). This allowed us to calculate the 













and 4, respectively, were attached to BSA. Accordingly, 12-BSA, 2-BSA and 4-BSA but 
not BSA yielded a coloured band upon periodate-Schiff staining for carbohydrate (Figure 
5B). Gels were next stained with Coomasie Brilliant blue to reveal total proteins (Fig 5C). 
Densitometric analyses indicated an apparent lower carbohydrate/protein ratio of 4-BSA 
(0.321) as compared to 12-BSA (0.884) and 2-BSA (0.972), hence further supporting its 
reduced content (on molar basis) of attached carbohydrates. BSA contains 59 units of 
lysine per molecule [56]. The degree of glycosylation achieved (Table 1) although not 
complete, was similar to that obtained by other authors [53].  
 
Table 1. Sugar load of the neoglycoconjugates 2-BSA, 4-BSA and 12-BSA 
  Molecular  weight (Da) Glycotope /BSA  Conjugation  
Calculated Experimental ratio efficiency (%) 
BSA 66500 66410   
12 389.1686    
2 551.2214    
4 713.2742    
12-BSA  78880 34.8 70 
2-BSA  86342 38.3 77 
4-BSA  86356 29.3 59 
 
 
The immunological validation of the synthesized neoglycoconjugates was performed 
using an ELISA format and a panel of human serum saples. As shown in Fig 6A, 2-BSA 
and 4-BSA were recognized in a dose-dependent manner by anti α-Gal antibodies affinity-
purified from Chagas positive sera but not by antibod es purified from Chagas negative 
sera. Conversely, and in accordance with previous results [16], 12-BSA was not recognized 
by anti α-Gal antibodies purified from Chagas positive sera (Figure 6A).  
We next assessed the recognition of the neoglycoconjugates by chronic Chagasic 
sera. In this case, an additional conjugate, from BSA coupled to a synthetic peptide 
spanning an immunodominant sequence from T. cruzi Antigen 2 (BSA-TcAg2) was 
included in the analysis for comparison purposes. Paired comparisons between signals 
obtained for Chagas disease positive and negative sera indicated that 4-BSA, 2-BSA and 
BSA-TcAg2, but neither 12-BSA nor BSA, display statistically significant differences in 













Chagas disease serodiagnosis (Figure 6B). 4-BSA and 2-BSA yielded highly variable and 
dispersed (i.e. not normally distributed) reactivity profiles, with few positive sera 
displaying high signals and most of them exhibiting moderate or negative signals (Figure 
6B). Most interestingly, 4-BSA and 2-BSA displayed quite similar reactivity towards 
individual serum samples (Figure 6C), strongly suggesting they are exposing similar 
glycotope(s) on their attached carbohydrates. In this context, it is worth noting that 
previous glycoarray-based data [16] mapped the binding of anti-α-Gal antibodies from 
Chagasic patients mainly to the disaccharide α-D-Galp-(1→3)-β-D-Galp (2), which is 
conserved between 4-BSA and 2-BSA. 
To further address this issue, we performed competitiv  ELISA assays. Plates were 
coated with 4-BSA and assayed with 3 chronic Chagasic sera (selected on the basis of their 
reactivity to this molecule as shown in Fig 6B). For c mpetition studies, and before being 
added to the plate, serum samples were incubated for 30 min with 10 µg of compound 12, 
2 or 4 diluted in PBS (phosphate buffered saline). As shown in Fig 6D, pre-incubation with 
compounds 2 or 4 yielded inhibition of 4-BSA recognition by Chagasic sera whereas pre-
incubation with compound 12 or PBS had a negligible effect on this phenomenon. 
Moreover, competition with compound 4 did not yield an improved inhibition as compared 
to compound 2, strongly suggesting that 2 is the main target of anti-α Gal antibodies 
elicited during T. cruzi infection. Neither compound 2 nor compound 4 were able to inhibit 
BSA-TcAg2 recognition by the same set of Chagas positive sera, fu ther supporting the 
specificity of competition results (Figure 6D).  
Taken together, these results indicate i) that antiα-Gal obtained from Chagas 
positive sera recognize neoglycoconjugates 2-BSA and 4-BSA; ii) that this recognition can 
be explained by or ascribed to their attached carbohydrates; and iii) that, as previously 
proposed [16], the disaccharide 2 bears the main glycotope recognized by anti-α-Gal 
antibodies elicited during T. cruzi infections. Most importantly, our data support 2-BSA 
and 4-BSA neoglycoconjugates as suitable reagents to improve Chagas disease diagnostic 
















Figure 6. Immunological validation of neoglycoconjugates. A) Reactivity of anti α-Gal 
antibodies purified from Chagas positive sera (circles) or antibodies purified from Chagas 
negative sera (squares) against 4-BSA (red), 2-BSA (green) and 12-BSA (blue) 
neoglycoconjugates. Each point was tested in duplicate and mean  ± SD OD450nm values are 
plotted against antibody concentration. Significant differences between the indicated 
populations' medians were evaluated by the ANOVA and Tukey post-test, and the p values 
are informed. Non-significant differences are denotd as ns. B) Dot plot analysis of 
reactivity values (expressed as the % of reactivity of a control Chagas negative serum 
assayed in parallel) using unconjugated BSA, 12-BSA, 2-BSA, 4-BSA and BSA-TcAg2. 
The ELISA plates were coated with the indicated antige  and incubated with 19 serum 
samples from chronic Chagas-positive individuals (+) or 6 Chagas negative individuals (-). 
The median and SD for each group are indicated by box and whiskers. Significant 
differences between the indicated populations' medians were evaluated by the Mann-
Whitney test, and the p values are informed. Non-sig ificant differences are denoted as ns. 













in parallel) of 6 selected serum samples from Chagas-positive individuals towards 12-BSA 
(blue), 4-BSA (red), 2-BSA (green), BSA-TcAg2 (purple) or BSA (orange). Each point 
was tested in duplicate and mean ± SD OD450nm values were indicated. D) Reactivity 
values (expressed as the % of reactivity of PBS-added sera) towards 4-BSA or BSA-
TcAg2 of 3 Chagasic serum samples treated with 10 µg of the indicated glycan before 





The synthesis of trisaccharide 4 was achieved using a synthetic path somewhat 
different from those reported for similar glycosides. Conjugation to BSA of 4 and the 6-
aminohexyl α-D-Galp-(1→3)-β-D-Galp was performed by the squarate method which 
allowed the direct derivatization of the lysines amino groups by the carbohydrate moieties. 
The synthesized neoglycoconjugates were successfully characterized both structurally and 
functionally. They were specifically recognized by serum samples of T. cruzi-infected 
patients, indicating they constitute suitable, and much needed tools for improve diagnostic 





4.1 General Methods 
The solvents used were distilled, dried and stored according to standard procedures. 
Analytical thin layer chromatography (TLC) was performed on Silica Gel 60 F254 (Merck) 
aluminium supported plates (layer thickness 0.2 mm). Visualization of the spots was 
effected by exposure to UV light, charring with 5% (v/v) sulfuric acid in EtOH containing 
0.5% p-anisaldehyde, or with 0.25% ninhydrin in acetone with traces of pyridine. Column 
chromatography was carried out with Silica Gel 60 (230–400 mesh, Merck) and for reverse 
phase with RP18/ graphitized carbon Strata™ catridges (500 mg/6ml) from Phenomenex. 













magnetic resonance (NMR) spectra were recorded with a Bruker AMX 500 instrument. 
Chemical shifts (δ) are reported in ppm, relative to chloroform (δ 7.27 for 1H and δ 77.16 
for 13C). Assignments of 1H and 13C NMR spectra were assisted by 2D 1H COSY and 
HSQC experiments. High resolution mass spectra (HRMS) were obtained by Electrospray 
Ionization (ESI) and Q-TOF detection. UV-MALDI-TOF analysis of the conjugates was 





glucopyranoside (9)  
To a suspension of 4-methylphenyl 1-thio-β-lactoside (8, 1.5 g, 3.34 mmol) [42] in 
dry toluene (80 mL), Bu2SnO (1.72 g, 2 equiv) was added and the mixture was stirred 
under reflux using a Dean-Stark trap to remove the formed water. After 4 h complete 
dissolution of the starting material was observed. The solution was brought to room 
temperature and after addition of NBu4I (0.14 g, 0.45 equiv) and 4-methoxybenzyl chloride 
(0.13 mL, 4.0 mmol, 1,2 equiv) the mixture was refluxed overnight using a conventional 
reflux condenser. Then, TLC analysis showed the formation of a product of Rf 0.33 (9:1 
CH2Cl2-MeOH) and some unreacted 8 (Rf 0.08). The mixture was filtrated, the filtrate was 
concentrated under reduce pressure and column chromatography (9:1 CH2Cl2-MeOH). 
afforded compound 9 as a syrup (0.80 g; 43 %), [α]D –14 (c 1; MeOH). 1H NMR (500 
MHz, DMSO-d6): δ 7.38-6.87 (m, 8H, aromatic), 4.60 (d, 1H, J 11.9 Hz, OCH2aAr), 4.58 
(d, 1H, J 10.1 Hz, H-1), 4.46 (d, 1H, J 11.7 Hz, OCH2bAr), 4.25 (d, 1H, J 7.8 Hz, H-1´), 
3.88 (d, 1H, J 3.4 Hz, H-4´), 3.74-3.53 (m, 4H, H-6a, H-6b, H-6´a, H-6´b), 3.73 (s, 3H, 
CH3O), 3.43-3.30 (m, 4H, H-3, H-4, H-5 and H-5´), 3.23 (dd, 1H, J 9.6, 3.1 Hz, H-3´), 3.08 
(td, 1H, J 8.8, 6.0 Hz, H-2´), 2.27 (s, 3H, CH3Ar) ppm. 
13C NMR (126 MHz, DMSO-d6): δ 
158.7, 136.5, 131.1, 130.9, 130.3, 129.6, 129.4, 113.6 (aromatics), 103.7(C-1´), 87.1(C-1), 
80.8 (C-3’), 80.1, 78.8, 76.4, 75.5 (C-3, C-4, C-5 and C-5´), 72.2 (C-2), 70.0 (CH2OAr), 
69.7 (C-2´), 64.7 (C-4´), 60.5, 60.4 (C-6 and C-6´), 55.2 (CH3O), 20.7 (CH3Ar).
 ESIMS: 
m/z calcd for C27H36O11SNa [M+Na]
















To a solution of 9 (0.75 g, 1.31 mmol) in anhydrous pyridine (9 mL) stirred at 0 °C, 
BzCl was added (3 ml, 4.8 equiv), and the stirring was continued overnight at room 
temperature. TLC analysis showed complete conversion of the starting material to a faster 
moving product (Rf 0.72, 1:1 hexane-AcOEt). The excess BzCl was quenched by addition 
of water (1 mL) and after 0.5 h of stirring the solution was diluted with CH2Cl2 (100 mL) 
and washed successively with water (100 mL), saturated NaHCO3 (ss) and water (100 mL), 
and dried (Na2SO4). The solution was concentrated under reduced pressu  and co-
evaporated several times with toluene. Crude product (10, 1.39 g, 89 %) was used for the 
following reaction without further purification. A fraction of the crude product was purified 
by column chromatography (3:1 hexane-AcOEt), [α]D +13 (c 1, CHCl3). 1H NMR (500 
MHz, CDCl3): δ 8.13-6.51 (m, 38 H, arom.), 5.74 (t, 1H, J 9.3 Hz, H-3), 5.61 (d, 1H, J 3.3 
Hz, H-4’), 5.41 (dd, 1H, J 9.7, 7.7 Hz, H-2’), 5.38 (dd, 1H, J 9.7 Hz, H-2), 4.82 (d, 1H, J 
10.0 Hz, H-1), 4.61 (d, 1H, J 8.0 Hz, H-1’), 4.56 (dd, 1H, J 11.9, 1.9 Hz, H-6a), 4.52 (d, 
1H, J 12.5 Hz, OCH2aPh), 4.41 (dd, 1H, J 11.9, 5.4 Hz, H-6b), 4.29 (d, 1H, J 12.5 Hz, 
OCH2bPh), 4.04 (t, 1H, J  9.5 Hz, H-4), 3.82 (ddd, 1H, J 9.9, 5.3, 2.0 Hz, H-5), 3.71 (dd, 
1H, J 11.2, 5.8 Hz, H-6’a), 3.68 (m, 1H, H-5’), 3.67 (s,3H, CH3O), 3.59 (dd, 1H, J 10.0, 
3.3 Hz, H-3’), 3.51 (dd, 1H, J 10.8, 6.5 Hz, H-6’b), 2.23 (s, 3H, CH3Ar) ppm. 
13C NMR 
(126 MHz, CDCl3): δ 165.8, 165.7, 165.5, 165.4, 165.2, 164.7 (COBz), 159.1, 138.3, 133.7, 
133.6, 133.3, 133.25, 133.20, 133.1, 133.0, 130.2, 130.1, 129.9, 129.8, 129.79, 129.71, 
129.6, 129.5, 129.4, 129.3, 129.2, 129.1, 129.0, 128.6, 128.4, 128.1, 127.8, 113.6 
(aromatics), 101.1 (C-1’), 86.0 (C-1), 77.2 (C-5), 76.0 (C-4), 75.7 (C-3’), 74.1 (C-3), 71.4 
(C-5’), 71.3 (C-2’), 70.4 (OCH2Ph), 70.3 (C-2), 66.0 (C-4’), 62.7 (C-6), 61.5 (C-6’), 55.1 




4.2.3 4-Methylphenyl 2,3,6-tri-O-benzoyl-β-D-galactopyranosyl-(1→3)-2,3,6-tri-O-benzoyl 
-1-thio-β-D-glucopyranoside (7) 
To a solution of 10 (1.64 g, 1.37 mmol) in CH2Cl2-H2O (22:1, 23 mL) DDQ (0.77 g, 













showed the presence of a product with Rf 0.41 (2:1 hexane-EtOAc) and remaining starting 
material (Rf 0.58). After adding 0.02 g more of DDQ the reaction was completed in 2 h. 
The solution was diluted with CH2Cl2 (100 mL) and the organic phase was washed 
successively with saturated NaHCO3 (ss) (2 x 50 ml), water (100 mL), dried (Na2SO4) and 
concentrated under reduced pressure. The residue was purified by column chromatography 
(3:1 hexane-EtOAc) to afford 7 as an amorphous solid (1.05 g, 72 %), [α]D +27 (c 1, 
CHCl3). 
1H NMR (500 MHz, CDCl3): δ 8.11- 6.91 (m, 34 H, H-arom.), 5.72 (t, 1H, J 9.4 
Hz, H-3), 5.49 (d, 1H, J 3.4 Hz, H-4’), 5.41 (t, 1H, J 9.8 Hz, H-2), 5.29 (dd, 1H, J 10.0, 7.8 
Hz, H-2’), 4.83 (d, 1H, J 10.0 Hz, H-1), 4.72 (d, 1H, J 7.9 Hz, H-1’), 4.70 (d, 1H, J 1.9, 
12.0 Hz, , H-6a), 4.57 (dd, 1H, J 12.0, 5.2 Hz, H-6b), 4.11 (t, 1H, J 9.6 Hz, H-4), 3.95 (dd, 
1H, J 10.0, 3.5 Hz, H-3’), 3.88 (ddd, 1H, J 10.0, 5.1, 1.9 Hz, H-5), 3.77-3.65 (m, 2H, H-
5’and H-6’a), 3.52-3.43 (m, 1H, H-6’b), 2.25 (s, 3H, CH3Ar) ppm. 
13C NMR (126 MHz, 
CDCl3): δ 166.5, 165.9, 165.8, 165.6, 165.5, 165.1 (CO), 138.4, 133.8, 133.5, 133.4, 133.3, 
133.0, 130.15, 130.1, 129.9, 129.62, 129.56, 128.8, 12 .62, 128.57, 128.5, 128.45, 128.37, 
128.1, 127.7 (aromatics), 100.6 (C-1`), 86.1 (C-1), 77.1 (C-5), 75.9 (C-4), 74.0 (C-3), 73.7 
(C-2’), 71.9 (C-3’), 71.5 (C-5’), 70.2 (C-2), 70.0 (C-4’), 62.8 (C-6), 61.3 (C-6’), 21.2 
(CH3Ar) ppm. ESIMS: m/z calcd for C61H52O16SNa [M+Na]





To a stirred suspension of trichloroacetimidate 6 (0.45 g, 0.65 mmol) [40] in 
anhydrous Et2O (10 mL) containing 4 Å activated MS under argon atmosphere cooled at 
−55 ºC, a solution of disaccharide acceptor 7 (0.56 g, 0.52 mmol) in anhydrous Et2O (7 
mL)  and TMSOTf (38 µL, 0.21 mmol) were added and the stirring was continued for 18 h. 
The reaction was quenched with Et3N, filtered and concentrated under reduced pressure. 
The residue was purified by column chromatography (7:2 hexane-EtOAc). Fractiond of Rf  
0.29 gave compound 5 (0.68 g, 65 %) as a foamy solid, [α]D +27 (c 1, CHCl3). 
1H NMR 
(500 MHz, CDCl3): δ 8.05-6.88 (m, 54 H, H-arom.), 5.75 (t, 1H, J 9.3 Hz, H-3), 5.61 (d, 
1H, J 3.3 Hz, H-4’), 5.58 (dd, 1H, J 10.1, 7.9 Hz, H-2’), 5.39 (t, 1H, J 9.7 Hz, H-2), 5.06 













(d, 2H, J 8.4 Hz, H-1’ and H-6a), 4.46 (dd, 1H, J 11.9, 5.2 Hz, H-6b ), 4.41 (dd, 2H, J 12.0, 
4.4 Hz, OCH2Ph), 4.36 - 4.33 (m, 2H, OCH2Ph), 4.23 (d, 3H, J 11.7 Hz, OCH2Ph), 4.04 (t, 
1H, J 9.5 Hz, H-4), 3.98 (dd, 1H, J 10.1, 3.3 Hz, H-3’), 3.85 (dd, 1H, J 10.3, 5.0 Hz, H-5), 
3.80 (dd, 1H, J 10.1, 3.4 Hz, H-2’’), 3.74- 3.68 (m, 2H, H-5’’ and H-6’a), 3.59 (t, 1H, J 6.5 
Hz, H-5’), 3.44 (dd, 1H, J 10.1, 2.8 Hz, H-3’’), 3.38 (dd, 1H, J 11.3, 6.9 Hz, H-6’b), 3.22 
(dd, 1H, J 9.2, 6.5 Hz, H-6’’a), 3.19 (d, 1H, J 2.9 Hz, H-4’’), 3.11 (dd, 1H, J 9.3, 6.1 Hz, 
H-6’’b), 2.23 (s, 3H, CH3Ar) ppm. 
13C NMR (126 MHz, CDCl3): δ 165.7, 165.6, 165.5, 
165.4, 165.1, 164.4 (CO), 138.7, 138.4, 138.3, 138.2, 133.7, 133.29, 133.22, 133.18, 132.8, 
130.1, 129.8, 129.7, 129.63, 129.57, 129.5, 129.3, 129.1, 128.9, 128.6, 128.5, 128.41, 
128.38, 128.35, 128.31, 128.2, 128.1, 128.05, 128.02, 128.0, 127.9, 127.8, 128.7, 127.67, 
127.60, 127.4, 127.3, 127.2, 127.1, 127.0 (aromatics), 101.2 (C-1’), 94.6 (C-1’’), 85.9 (C-
1), 78.5 (C-3’’), 77.2 (C-5), 76.0 (C-4), 75.1 (C-2’’), 74.8 (C-4’’), 74.4 (OCH2Ph), 74.1 (C-
3), 73.2 (OCH2Ph), 73.1 (OCH2Ph), 73.0 (C-3’), 72.3 (OCH2Ph), 71.6 (C-5’), 71.1 (C-2’), 
70.2 (C-2), 69.8 (C-5’’), 68.8 (C-6’’), 65.7 (C-4’), 62.6 (C-6), 61.3 (C-6’), 21.1 (CH3Ar) 
ppm. ESIMS: m/z calcd for C95H86O21SNa [M+Na]+ 1617.5280. Found: 1617.5201. 
 
4.2.5  6-Benzyloxycarbonylaminohexyl 2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl-
(1→3)-2,4,6-tri-O-benzoyl-β-D-galactopyranosyl-(1→4)-2,3,6-tri-O-benzoyl-β-D-
glucopyranoside (11) 
 Thioglycoside 5 (0.26 g, 0.16 mmol), 6-benzyloxycarbonylamino-1-hexanol (0.058 g, 
0.23 mmol, 1.4 equiv) and NIS (0.04 g, 0.18 mmol, 1.1 equiv) were dissolved in anhydrous 
CH2Cl2 (5 mL) containing 4 Å activated molecular sieves. The solution was cooled at −10 
ºC and then TfOH (2 µL, 0.02 mmol) was added. After 12 h of stirring at rt the mixture was 
filtered and diluted with CH2Cl2 (100 mL), extracted with NaHCO3 (ss) and Na2S2O4 (50 
mL, 10 % v/v), washed with water (2 x 25 mL), dried (Na2SO4) and concentrated under 
reduced pressure. The crude product was purified by column chromatography (15:2 
toluene-EtOAc) to give 11 (0.21 g, 74%) as white foam, [α]D +32 (c 1, CHCl3). 
1H NMR 
(500 MHz, CDCl3): δ 8.07-6.94 (55 H, H-arom.), 5.76 (t, 1H, J 9.5 Hz, H-3), 5.61 (d, 1H, J 
2.8 Hz, H-4’), 5.59 (dd, 1H, J 8.0, 10 Hz, H-2’), 5.42 (dd, 1H, J 9.9, 7.9 Hz, H-2), 5.07 (s, 
2H, CH2Cbz), 5.05 (d, 1H, J 3.4 Hz, H-1’’), 4.66-4.62 (m, 3H, H-1, H-1’ and OCH2Ph), 













11.9, 4.9 Hz, OCH2Ph), 4.34 (d, 2H, J 11.7 Hz, OCH2Ph), 4.22 (dd, 3H, J 11.7, 6.2 Hz, 
OCH2Ph), 4.14 (t, 1H, J 9.5 Hz, H-4), 3.96 (dd, 1H, J 10.1, 3.3 Hz, H-3’), 3.82-3.70 (m, 
5H, H-2’’, H-5, H-5’’, H-6’a and OCH2a), 3.59 (t, 1H, J 6.5 Hz, H-5’), 3.44 (d, 1H, J 2.8, 
10 Hz, H-3’’), 3.43-3.39 (m, 2H, OCH2b and H-6’b), 3.19 (m, 2H, H-6’’a and H-4’’), 3.11 
(dd, 1H, J 9.3, 6.2 Hz, H-6’’b), 2.98 (q, 2H, J 6.6 Hz, CH2N), 1.53 (m, 2H, CH2), 1.20-1.07 
(m, 2 CH2) ppm. 
13C NMR (126 MHz, CDCl3): δ 165.8, 165.6, 165.5, 165.4, 165.1, 164.5 
(CO), 138.8, 138.5, 138.2, 133.4, 133.23, 133.20, 13 .1, 129.8, 129.7, 129.6, 129.5, 129.4, 
128.6, 128.5, 128.4, 128.3, 128.1, 128.0, 127.9, 127.8, 127.6, 127.3, 127.0 (aromatics), 
101.2 (C-1’), 101.1 (C-1), 94.7 (C-1’’), 78.6 (C-3’’), 76.0 (C-4), 75.1 (C-2’’), 74.9 (C-4’’), 
74.4 (OCH2Ph), 73.3, 73.1, 73.0 (C-5, C-3’ and 2 OCH2Ph), 72.8 (C-3), 72.3 (OCH2Ph), 
71.7 (C-2), 71.6 (C-5’), 71.1 (C-2’), 70.0 (CH2O), 69.8 (C-5’’), 68.7 (C-6’’), 66.5 
(CH2Cbz), 65.8 (C-4’), 62.5 (C-6), 61.4 (C-6’), 40.8 (CH2N), 29.6, 29.1, 26.1 and 25.4 (4 
CH2) ppm. ESIMS: m/z calcd for C102H99O24NaN [M+H]
+ 1722.6635. Found: 1722.6646. 
 
4.2.6   6-Aminohexyl α-D-galactopyranosyl-(1→3)-β-D-galactopyranosyl-(1→4)-β-D-
glucopyranoside (4) 
Trisaccharide 11 (0.17 g, 0.1 mmol) was dissolved in CH2Cl2 (1 mL) and treated with 
a cooled solution of 0.1 M NaOMe in MeOH (8 mL). After 3 h of stirring at rt TLC showed 
total conversion of 11 (Rf 0.46, 9:0.3 CH2Cl2-MeOH) into a compound of Rf 0.15. The 
solution was concentrated under reduced pressure in order to evaporate the CH2Cl2 and 
then deionized by elution with MeOH trough a column loaded with Amberlite IR-120 plus 
resin (200 mesh, H+ form). The eluate was concentrated under reduced pr ssure and 
coevaporated several times with water to afford a white solid (0.10 g, 93%). [α]D +28 (c 1, 
CHCl3); 
1H NMR (500 MHz, D2O): anomeric signals δ 4.86 (m, 2H, H-1’ and CH2Ph), 
4.32 (d, 1H, J1’’,2’’ = 7.7 Hz, H-1”), 4.17 (d, 1H, J1,2 = 7.8 Hz, H-1); 
13C NMR (126 MHz, 
D2O): anomeric region δ (ppm) 103.9 (C-1”), 103.1 (C-1), 96.0 (C-1’).  
The solid was dissolved in methanol (9.5 mL) containing 5% of formic acid and 10 % 
Pd/C (20 mg). The mixture was hydrogenated at 55 psi until all the starting material was 
converted into a lower running component (Rf 0.23, 3:2:0.1 CH2Cl2-MeOH-NH4OH) (48 h). 
After filtration, the solution was concentrated under reduced pressure, redissolved in water 













MeOH. Fractions of Rf 0.23 were concentrated under reduced pressure, to afford 4 (0.48 g, 
98 %). [α]D +29 (c 0.5, CH3OH); 1H NMR (500 MHz, D2O): δ 5.15 (d, 1H, J 3.9 Hz, H-
1’’), 4.52 (d, 1H, J 7.8 Hz, H-1’), 4.49 (d, 1H, J 8.0 Hz, H-1), 4.21-4.18 (d, 2H, H-5’’ and 
H-4’), 4.03- 3.90 (m, 4H, H-4’’, H-6a, H-3’’ and OCH2a), 3.87 (dd, 1H, J 10.4, 3.8 Hz, H-
2’’), 3.83-3.57 (m, 12H, H-6b, H-6’a, H-6’b, H-6’’a, H-6’’b, H-5, H-5’, H-4, H-3, H-3’, H-
2’ and OCH2b), 3.31 (td, 1H, J 8.0, 2.4 Hz, H-2), 3.00 (t, 2H, J 7.6 Hz, NCH2), 1.66 (dp, 
4H, 2 CH2), 1.41 (p, 4H, 2 CH2) ppm. 
13C NMR (126 MHz, D2O): δ 102.8 (C-1’), 102.0(C-
1), 95.4 (C-1’’), 78.7, 77.2, 75.0, 74.7, 74.5, 69.6 (C-4, C-3’, C-5, C-3, C-2’ and C-5’), 
72.80 (C-2), 70.8 (C-5’’), 70.4 (CH2), 69.3 (C-3’’), 69.1 (C-4’’), 68.2 (C-2’’), 64.8 (C-4’), 
61.0, 60.9, 60.2 (C-6, C-6’ and C-6’’), 39.4 (CH2N), 28.4, 26.6, 25.2, 24.5 (CH2) ppm. 




To a solution of 4 (0.025 g, 0.046 mmol) in 0.1 M KH2PO4-NaOH buffer (pH 7, 
3.57 ml) 3,4-dimethoxy-3-cyclobutene-1,2-dione (13 mg, 0.09 mmol) was added and the 
solution was stirred at room temperature. The pH was m intained at 7 by addition of small 
amounts of Et3N (10 µL). TLC examination after 24 h of reaction showed total conversion 
of 4 (Rf 0.23, 3:2:0.1 CH2Cl2-MeOH-NH4OH) into a faster moving compound (Rf 0.43). 
The solution was concentrated under reduced pressur and purified by passing through a 
graphitized carbon SPE column (500 mg). The column was eluted with water (10 mL) 
followed by a step gradient from 0 to 40 % of CH3 N in water. By concentration of 
fractions eluted with 40 % CH3CN compound 4-sq was obtained (15 mg, 46 %) as a 
syrup. 1H NMR (500 MHz, D2O): δ 5.15 (d, 1H, J 3.9 Hz, H-1’’), 4.53 (d, 1H, J 7.8 Hz, 
H-1’), 4.48 (d, 1H, J 8.0 Hz, H-1), 4.38-4.36 (m, 3H, CH3O-squaratea and CH3O-
Ssquarateb), 4.23-4.18 (m, 2H, H-5’’ and H-4’), 4.03-3.89 (m, 4H, H-4’’, H-6a, H-3’’ and 
OCH2a), 3.87 (dd, 1H, J 10.4, 3.8 Hz, H-2’’), 3.83-3.57 (m, 7H, H-6’a, H-6b, H-6’b, H-
6’’a, H-6’’b, H-4, H-3’, H-5, H-2’, H-3, H-5’ and OCH2b, NHCH2-squaratea), 3.48 (t, 1H, 
J 6.8 Hz, NHCH2-squarateb), 3.33-3.28 (m, 1H, H-2), 1.64 (d, 4H, J 6.9 Hz, 2 CH2), 1.41-
1.36 (m, 4H, 2 CH2) ppm. 
13C NMR (126 MHz, D2O): δ 189.2, 183.2, 183.0, 177.6, 













74.5, 69.6 (C-2’, C-3, C-3’, C-4, C-5 and C-5’), 72.8 (C-2), 70.8 (C-5’’), 70.5 (OCH2), 
69.3 (C-3’’), 69.1 (C-4’’), 68.2 (C-2’’), 64.8 (C-4’), 61.0, 60.9, 60.8, 60.7, 60.2 (C-6, C-
6’, C-6’’, CH3Oa and CH3Ob), 44.5, 44.3 (CH2N), 29.7, 29.4, 28.5 x 2, 25.2, 25.1, 24.6, 




 A solution of 12 (7 mg, 0.0098 mmol) and BSA (0.013 g, 1.96x10-4 mmol) in a 
molar ratio 50:1, in 0.05 M borax -0.1 M KH2PO4 buffer (pH 9, 0.98 ml) was stirred at 
room temperature. The pH was maintained at 9 by addition of small amounts of Et3N (10 
µL were necessary). By TLC the gradual conversion of 12 (Rf 0,43 CH2Cl2-MeOH-
NH4OH 3:2:0.1) into components of Rf 0 was observed. The solution dialyzed against 
deionized water using a MWCO 12000-14000 membrane and the retained solution was 
lyophilized to afford conjugate 4-BSA (13.4 mg, 79 %) as an amorphous white powder.  
 
4.3  MALDI-TOF MS 
The MALDI-TOF spectra were recorded in positive ion mode. Each sample was 
dissolved in 2 % acetic acid and 2 % acetonitrile aqueous solution, to give a final 300 µM 
sample solution. Pre-loading mix was prepared by adding 5 µL of sample solution to 5 µL 
of matrix solution (sinapinic acid 10 mg/mL in 7:3 acetonitrile-water containing 0.1 % 
TFA). The mixture (1 µL) was applied to the MALDI-plate spot and allowed to air dry. 
Once dried, 1000 adquisitions shots were fired per s ot and the accumulated final spectra 
were saved. 
 
4.4  SDS-PAGE 
Aliquots containing ~1 µg of protein taken at the indicated conjugation times were 
analyzed by SDS-PAGE (10 % gels). Commercial bovine submaxillary mucin (BSM, 
Sigma) was used as positive control. The gels were stained with Coomassie brilliant blue 
or subjected to the periodate-Schiff staining technique [57] and, following image 
acquisition, counterstained with Coomassie brilliant blue. Densitometric analyses were 














4.5  Immunological assays 
4.5.1  Serum samples 
Serum samples from T. cruzi-infected subjects have been described [4][46][56] and
were obtained from the Laboratorio de Enfermedad de Chagas, Hospital de Niños "Dr. 
Ricardo Gutierrez". All procedures were approved by the research and teaching committee 
and the bioethics committee of this institution, and followed the Declaration of Helsinki 
Principles. Written informed consent was obtained from all individuals (or from their legal 
representatives), and all samples were decoded and e-identified before they were provided 
for research purposes. Chagasic patients were coursing the chronic stage of the disease 
without cardiac or gastrointestinal compromise. Serum samples were analyzed for T. cruzi-
specific antibodies with the following commercially available kits: ELISA using total 
parasite homogenate (Wiener lab, Argentina) and indirect hemmaglutination assay (IHA, 
Polychaco, Argentina). Serum samples from healthy indiv duals that gave negative results 
in the aforementioned tests were obtained from different blood banks: Fundación 
Hemocentro Buenos Aires (Buenos Aires, Argentina), Hospital de Enfermedades 
Infecciosas ‘Dr. Francisco Javier Muñiz’ (Buenos Aires, Argentina), Hospital Italiano de 
Buenos Aires (Buenos Aires, Argentina) and Hospital Municipal ‘Dr. Diego E. Thompson’ 
(San Martín, Buenos Aires, Argentina). Anti-α-Gal antibodies were obtained by affinity 
chromatography of serum samples from chronic Chagasic patients on silica particles linked 
to trisaccharide 1 as described [58], whereas antibodies from Chagas-negative individuals 
were obtained by protein-A affinity chromatography [4].  
 
4.5.2 Enzyme-linked immunosorbent assay (ELISA)  
ELISA tests were performed using flat-bottomed 96-well Nunc-Immuno plates 
(Nunc, Roskilde, Denmark), as described previously [59]. Briefly, BSA-based 
glycoconjugates were dissolved in carbonate buffer (pH 9.6) as a coating buffer at 10 
µg/ml and incubated overnight at 4°C. The plates were blocked for 1 h with PBS 
supplemented with 4% skim milk  and 0.05% Tween 20 (blocking buffer) at 37°C. Serum 
samples were prepared in blocking buffer (at 1:500 dilution) were then added to the plate. 













before being added to the plate. Following incubation for 1 h at 37°C and washings with 
PBS/T, peroxidase-conjugated goat IgG to human IgG (Sigma) diluted 1:5,000 in 4% skim 
milk in PBS/T was added to the plates and incubated t 37°C for 1 h. The plates were 
washed and incubated with 100 µl of freshly prepared citrate-phosphate buffer (pH 4.2) 
containing 0.2% hydrogen peroxide and 0.5 mM 3,3’,55 -tetramethylbenzidine (Sigma). 
The reaction was stopped with 50 µl of 2 M sulfuric acid, and the absorbance at 450 nm 
was read. Each sample was assayed in triplicate, unl ss otherwise indicated. T. cruzi 
Antigen 2 (TcAg2) was identified by means of early immunological screenings [60], and 
its immunodominant sequences mapped by high-density peptide microarrays [47]. A 
TcAg2-derived peptide (sequence: NH2-KKKQKTAPFGQAAAGDKPSPFGQAC) was 
custom synthesized (GenScript) and coupled through its C-terminal cysteine residue to 
maleimide-activated BSA (Sigma) as described [61]. ELISA plates coated with 100 µl of a 
solution containing 5 µg/ml of this conjugate were pr pared and evaluated as described 
above. 
For competitive ELISA, the serum samples were diluted up to 10 µl in PBS 
containing 10 µg of the indicated synthetic carbohydrate. After 30 min of incubation at 
room temperature, the serum-carbohydrate mixtures were diluted up to 1:500 in 4 % skim 
milk PBS/T buffer, added to 4-BSA or BSA-TcAg2 coated plates, and processed by 
ELISA, as described above. Absorbance at 450 nm in the control wells in which the serum 
samples were incubated for 30 min with 10 µl of PBS without carbohydrate was taken as 
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Appendix: Supplementary material 
 Supplementary data to this article (NMR spectra fo compounds 4, 5, 7, 9, 10 and 11) 
can be found online at doi:…. 
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 Trisaccharide  α-D-Galp(1→3)-β-D-Galp(1→4)-D-GlcNAc is a main component of 
Trypanosoma cruzi trypomastigote mucins with immunological properties. 
 The analogue α-D-Galp(1→3)-β-D-Galp(1→4)-β-D-Glcp derivatized as the 6-aminohexyl 
glycoside was synthesized. This trisaccharide and the analogue glycoside of α-D-Galp(1-
3)-β-D-Galp, were conjugated to BSA by the squarate method. 
 ELISA assays revealed that these neoglycocojugates were recognized by sera from 
chagasic patients, indicating its potential as diagnostic tools. 
